Advanced searches left 3/3

Bv - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 28 August 2022

* If you want to update the article please login/register

Effectiveness and Safety for Re-treatment With Brentuximab-Vedotin (BV) in Patients With Relapsed/Refractory (R/R) CD30+ Malignancies: a Retrospective Medical Chart Review Study in Spain

Participants with R/R CD30 positive cHL, CTCL, and sALCL with R/R CD30 positive cHL, CTCL, and sALCL who had previously received a CR or PR with BV therapy and then experienced disease progression were given BV retreatment. This report will investigate the effects and safety of BV retreatment in the Spanish population in real-world clinical research.

Source link: https://clinicaltrials.gov/ct2/show/NCT04998331

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions